BCL2 and ovarian cancer: Although artemisinins have been preclinically evaluated in combination with Bcl-2 inhibitors in leukemia and non-small-cell lung cancer cells [24,25,26], the use of artesunate with navitoclax has not been investigated in ovarian cancer.